fosun pharma occupies front place in 2014 top 100 pharmaceutical enterprises in china
recently, southern medicine economic institute under china food and drug administration and medicine economic news office jointly released the “top 100 pharmaceutical enterprises in china”. fosun pharma was ranked in the 14th place, continuing its outstanding performance in the list over the years.
“top 100 pharmaceutical enterprises in china” was initiated in 2006 and the event is held for 9 sessions by this year. the pharmaceutical business of fosun pharma has participated in the selection for five consecutive years and has stably occupied front places.
pharmaceutical manufacturing is the core of fosun pharma’s pharmaceutical business development. in 2014, the company’s pharmaceutical manufacturing and r&d business recorded revenue of rmb 7,336.65 million. the company continued the heavy investments in the therapeutic areas of cardiovascular system, central nervous system, blood system, metabolism and alimentary system, anti-tumor and anti-infection. the sales of major products maintained rapid growth.
in 2014, the company had 17 formulation items and series with sales of over rmb 100 million, among which the sales of xihuang capsules and compound aloe jera capsules exceeded rmb 100 million for the first time and the sales of adegold and atomolan exceeded rmb 500 million. as of the end of 2014, the company has 16 apis (active pharmaceutical ingredients) and production lines with certifications from who-pq, the us fda, eu certification, ministry of health, labour and welfare of japan and federal ministry of health of germany, 4 production lines for formulation passed the who-pq certification, and health canada gmp certification.
“top 100 pharmaceutical enterprises in china” is selected and organized jointly by southern medicine institute under cfda and medicine economic news officeannually. it is influential in the medicine industry featuring with professionalism, exclusiveness and trueness.